Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.5%

5 terminated/withdrawn out of 37 trials

Success Rate

86.5%

-0.0% vs industry average

Late-Stage Pipeline

38%

14 trials in Phase 3/4

Results Transparency

13%

4 of 32 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

11(33.3%)

Phase 3

9(27.3%)

Phase 4

5(15.2%)

Phase 1

5(15.2%)

N/A

3(9.1%)

33Total

Phase 2(11)

Phase 3(9)

Phase 4(5)

Phase 1(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials

NCT00204945Not ApplicableCompleted

Catheterization Laboratory Study: Acute Responses in Diastolic Heart Failure

Role: collaborator

NCT00204984Not ApplicableCompleted

Heart and Blood Pressure Study: The Effect of Aortic Impedance on Myocardial Relaxation

Role: collaborator

NCT00530361Phase 3Withdrawn

An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)

Role: lead

NCT00505791Phase 4Withdrawn

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF

Role: collaborator

NCT00405548Phase 1Completed

Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.

Role: collaborator

NCT00186329Phase 4Completed

BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)

Role: collaborator

NCT00453453Phase 4Terminated

BNP Therapy Observation Unit Outcomes STudy (BOOST)

Role: collaborator

NCT00338455Phase 2Terminated

Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC

Role: lead

NCT00309868Phase 1Completed

Study of Nesiritide in Diastolic Heart Failure.

Role: collaborator

NCT00530426Completed

Heart Failure Registry

Role: lead

NCT00113893Phase 2Completed

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Role: lead

NCT00145873Phase 2Terminated

Nesiritide in Chronic Heart Failure

Role: collaborator

NCT00119691Phase 2Completed

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

Role: collaborator

NCT00240084Phase 2Completed

Nesiritide and Vo2 Max in Heart Failure Patients

Role: collaborator

NCT00475852Phase 3Completed

A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Role: lead

NCT00252187Phase 1Completed

Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure

Role: collaborator

NCT00270387Phase 3Completed

A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy

Role: lead

NCT00270361Phase 3Completed

FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.

Role: lead

NCT00270374Phase 3Completed

A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.

Role: lead

NCT00270400Phase 3Completed

A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure

Role: lead